國立虎尾科技大學 |

The New Drug Reimbursement Game = A Regulator’s Guide to Playing and Winning /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	The New Drug Reimbursement Game/ by Brita A.K. Pekarsky.
其他題名:	A Regulator’s Guide to Playing and Winning /
作者:	Pekarsky, Brita A.K.
面頁冊數:	XVI, 248 p. 9 illus.online resource. :
Contained By:	Springer Nature eBook
標題:	Pharmacy management. -
電子資源:	https://doi.org/10.1007/978-3-319-08903-4
ISBN:	9783319089034

The New Drug Reimbursement Game = A Regulator’s Guide to Playing and Winning /
Pekarsky, Brita A.K.

The New Drug Reimbursement GameA Regulator’s Guide to Playing and Winning /[electronic resource] :by Brita A.K. Pekarsky. - 1st ed. 2015. - XVI, 248 p. 9 illus.online resource.

Introduction -- Reframing the political economy of new drugs -- The social rate of return on investment in pharmaceutical R&D -- The value of innovation -- The shadow price -- The health shadow price -- The health shadow price and the economic context -- The `pharmaceutical R&D financing' game -- The `pharmacotherapy needs a premium' game -- Conclusion.

This comprehensive text presents a rigorous framework from within which regulators can respond strategically to the claim by the pharmaceutical industry that lower drug prices today lead to a loss for the population’s future health due to less innovation. It starts with a critical review of the empirical evidence of the return to consumers on their ongoing investment into high drug prices in order to increase future innovation. The implicit, critical and unrealistic assumption inherent in these studies is identified, namely that the health budget can be expanded to purchase drugs at higher prices without an opportunity cost, for example, the foregone benefits of alternative investments in health care infrastructure. Price effectiveness analysis (PEA), is introduced. PEA informs the question of how the innovative surplus from the new drug should be allocated between the manufacturer and the consumer so as to optimise society’s welfare. The method allows the decisions by the regulator and the firm to be analysed jointly by specifying the firm’s production and revenue functions in terms of the clinical innovation of a new drug; the incremental effect used in the summary metric of cost effectiveness analysis. An economic value of innovation that takes into account opportunity cost under conditions of economic efficiency in the health system is proposed: the health shadow price. The limitations of the non-strategic methods that currently inform the highly contested new drug subsidy game are presented and the relative strengths of PEA are demonstrated. Health technology assessment quantifies both the clinical innovation of a new drug and its financial impact on the health system. Cost effectiveness analysis tests the relationship between the incremental cost and incremental effect of a new drug for target patients, at a given price. PEA tests the relationship between the price of a new drug and the health of the whole population, now and into the future. It achieves this by taking into account current inefficiency in both resource allocation and the displacement process, and the relationship between price and future innovation.

ISBN: 9783319089034

Standard No.: 10.1007/978-3-319-08903-4doiSubjects--Topical Terms:

1236292
Pharmacy management.

LC Class. No.: RS100-100.4

Dewey Class. No.: 615.1

The New Drug Reimbursement Game = A Regulator’s Guide to Playing and Winning /
LDR:03851nam a22003975i 4500 001 965349
003 DE-He213
005 20200706221530.0
007 cr nn 008mamaa
008 201211s2015 gw | s |||| 0|eng d
020 $a 9783319089034 $9 978-3-319-08903-4
024 7 $a 10.1007/978-3-319-08903-4 $2 doi
035 $a 978-3-319-08903-4
050 4 $a RS100-100.4
072 7 $a MMG $2 bicssc
072 7 $a MED071000 $2 bisacsh
072 7 $a MKG $2 thema
082 0 4 $a 615.1 $2 23
100 1 $a Pekarsky, Brita A.K. $4 aut $4 http://id.loc.gov/vocabulary/relators/aut $3 1063576
245 1 4 $a The New Drug Reimbursement Game $h [electronic resource] : $b A Regulator’s Guide to Playing and Winning / $c by Brita A.K. Pekarsky.
250 $a 1st ed. 2015.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Adis, $c 2015.
300 $a XVI, 248 p. 9 illus. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
505 0 $a Introduction -- Reframing the political economy of new drugs -- The social rate of return on investment in pharmaceutical R&D -- The value of innovation -- The shadow price -- The health shadow price -- The health shadow price and the economic context -- The `pharmaceutical R&D financing' game -- The `pharmacotherapy needs a premium' game -- Conclusion.
520 $a This comprehensive text presents a rigorous framework from within which regulators can respond strategically to the claim by the pharmaceutical industry that lower drug prices today lead to a loss for the population’s future health due to less innovation. It starts with a critical review of the empirical evidence of the return to consumers on their ongoing investment into high drug prices in order to increase future innovation. The implicit, critical and unrealistic assumption inherent in these studies is identified, namely that the health budget can be expanded to purchase drugs at higher prices without an opportunity cost, for example, the foregone benefits of alternative investments in health care infrastructure. Price effectiveness analysis (PEA), is introduced. PEA informs the question of how the innovative surplus from the new drug should be allocated between the manufacturer and the consumer so as to optimise society’s welfare. The method allows the decisions by the regulator and the firm to be analysed jointly by specifying the firm’s production and revenue functions in terms of the clinical innovation of a new drug; the incremental effect used in the summary metric of cost effectiveness analysis. An economic value of innovation that takes into account opportunity cost under conditions of economic efficiency in the health system is proposed: the health shadow price. The limitations of the non-strategic methods that currently inform the highly contested new drug subsidy game are presented and the relative strengths of PEA are demonstrated. Health technology assessment quantifies both the clinical innovation of a new drug and its financial impact on the health system. Cost effectiveness analysis tests the relationship between the incremental cost and incremental effect of a new drug for target patients, at a given price. PEA tests the relationship between the price of a new drug and the health of the whole population, now and into the future. It achieves this by taking into account current inefficiency in both resource allocation and the displacement process, and the relationship between price and future innovation.
650 0 $a Pharmacy management. $3 1236292
650 0 $a Pharmaceutical technology. $3 557391
650 1 4 $a Pharmacoeconomics and Health Outcomes. $3 1063577
650 2 4 $a Pharmaceutical Sciences/Technology. $3 768561
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783319089041
776 0 8 $i Printed edition: $z 9783319089027
776 0 8 $i Printed edition: $z 9783319349206
856 4 0 $u https://doi.org/10.1007/978-3-319-08903-4
912 $a ZDB-2-SME
912 $a ZDB-2-SXM
950 $a Medicine (SpringerNature-11650)
950 $a Medicine (R0) (SpringerNature-43714)